Order Now 1-800-246-8878

DiaCarta’s team brings deep industry experience and a dedication to improving therapeutic options across the globe.

Our Mission

DiaCarta is a translational genomics and personalized diagnostics company based in Richmond, California. Our mission is to provide highly sensitive and advanced technologies that will improve the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world.

With over 18,000 square feet dedicated to a GMP-compliant lab space as well as CLIA and ISO 13485 certifications, DiaCarta is changing the landscape of molecular diagnostics.

Leadership

Aiguo Zhang, Ph.D.
President and CEO, Founder

Aiguo Zhang, Ph.D.

President and CEO, Founder

Dr. Zhang is an active entrepreneur and executive in the biotech and pharmaceutical industries with extensive experience ranging from startups to major corporations, including GainPep, Kodia, Panomics, Affymetrix and Bio-Rad. Dr. Zhang brings knowledge and an extensive network in Asia and Emerging Markets to his role at DiaCarta. His substantial experience in R&D management and capability building in Asia and Emerging Markets has a project scope ranging from discovery research to sales and marketing in both US and international markets. He received his Ph.D. from Simon Fraser University in molecular toxicology and pharmacology, was a postdoctoral scholar at the University of Massachusetts, and served as an assistant professor of research at the University of California, Berkeley. Dr. Zhang has published many research papers in leading scientific journals. His inventions are the subject of many patents and patent-pending applications.

Michael J. Powell, Ph.D.
Chief Scientific Officer

Michael J. Powell, Ph.D.

Chief Scientific Officer

Dr. Powell is a highly recognized scientific and business leader with more than 25 years experience in R&D, technology, and business and corporate development. Dr. Powell brings extensive knowledge and experience to DiaCarta in the fields of molecular diagnostic assay research and development, qPCR and other nucleic acid amplification technologies, and automated instrumentation platforms.

Dr. Powell was the Chief Scientist of Nanopoint Inc., a privately held nanobiotechnology company that developed a novel micro-fabricated (MEMS) slide-based imaging system and reagents for cell-based assays in the life sciences. He was also the founder of Odyssey Thera Inc., a privately held company that commercialized a proprietary fluorescent live cell-based assay and diagnostic imaging technology for the application in target validation and drug discovery.

Dr. Powell was the Director of New Technology at the Chief Technology Office of Roche Diagnostics (Roche acquired Boehringer Mannheim Corporation in May, 1997 for $11B). Prior to the acquisition by Roche he was Director of New Technology at Boehringer Mannheim Corporation (Boehringer Mannheim acquired Microgenics in June, 1992). Dr. Powell was also the Director of New Technology at Microgenics Corporation, in Concord, California. Dr. Powell has served on several other senior management teams including IGEN Inc., Integrated Genetics Inc., and Celltech PLC, UK.

Dr. Powell has published many research papers in leading scientific journals and holds over 25 patents and patent-pending applications. Dr. Powell introduced a rapid homogeneous mutation analysis method in his article, Detection of the Hereditary Hemochromatosis Gene Mutation by Real-Time Fluorescence Polymerase Chain Reaction and Peptide Nucleic Acid Clamping. Analytical Biochemistry. Volume 260, Issue 2.1 July 1998, Pages 142–148.

Dr. Powell received his Ph.D. in medicinal organic chemistry from Loughborough University, Loughborough, UK and Ph.D. from University of Nottingham, Nottingham, UK.

Elena Peletskaya, Ph.D.
Director of IVD

Dr. Peletskaya is a molecular biologist who serves as the Director of In Vitro Diagnostics at DiaCarta. Dr. Peletskaya has designed many novel protocols for molecular diagnostic analysis such as highly multiplexed PCR-based SNP genotyping assays. Her research has contributed to the understanding of the functional structures of retroviral proteins as related to drug resistance, cancer therapeutics, muscular system. Dr. Peletskaya has written and contributed to several scientific articles and has also presented her findings to international audiences.

Dr. Peletskaya received her schooling in Russia, completing her Ph.D. in Molecular Virology at The Russian Academy of Medical Sciences. Additionally, she has supplemented her expertise in the United States with a postdoctoral fellowship at the University of Missouri. Thereafter, Dr. Peletskaya obtained a Technical Supervisor certificate from the American Board of Bioanalysis, as well as the title of High Complexity Laboratory Director in molecular genetic testing from the New York Department of Health.

Dr. Peletskaya’s technical and scientific skills are complemented with a natural aptitude for managerial roles in CLIA- and CAP-certified laboratory settings. She has served as a Principal Scientist at Biolinx since 2003, where she provides consulting services at molecular genetic testing facilities. She has had project management roles in academic and startup biotech settings while simultaneously coordinating independent projects. Dr. Peletskaya has nurtured from inception several collaborative, contract research and development projects at institutions such as the National Cancer Institute at National Institute of Health, Fox Chase Cancer Center and has been awarded government research and SBIR grant funding and contract funding from NIH and universities for her research endeavors.

Effie Ho, Ph.D., MBA
GM, Asia Pacific

Effie Ho, MBA, PhD

GM, Asia Pacific

Effie brought in more than 15 years industrial experience to the company including many years at J&J and Pfizer. Specialized in drug and medical device’s business development strategies and RA/Clinical Development execution in emerging healthcare markets horizontally (strategy planning, RA and Clinical planning, local partner, raising capital, execution clinical planning , regulatory approval and vertically (execution of clinical development in China, Taiwan, Korea, HK) with proven records from IP to products. Obtained M.B.A. from Penn state University, PA, USA; Postdoc at Harvard Medical School, Boston, MA, Obtained PhD from Rutgers University, NJ, USA.

Medical Advisors

Anthony M. Magliocco, M.D.
Chair of Advisory Board

Read Bio

Anthony M. Magliocco, M.D.

Chair of Advisory Board

Dr Anthony (Tony) Magliocco is a Senior Member and Chair, Department of Anatomic Pathology at Moffitt Cancer Center as well as Executive Director of Esoteric Laboratory Services and the Morsani Molecular Diagnostic Laboratory, and Scientific Director of the Moffitt Tissue Core. He is Board Certified in anatomic pathology and completed a fellowship at the Fox Cancer Center and residency at the University of Calgary. Dr Magliocco has subspecialty expertise in breast, gynecological and molecular pathology and research interests in the areas of molecular predictive markers, digital analytical microscopy, and personalized medicine. He is also co-chair of pathology for the NRG cooperative clinical trials group, and was recently appointed to the NIH NCI Genitourinary Steering Committee.

Dr. Magliocco earned his M.D. at the University of Alberta, Edmonton, Canada. He completed an Anatomical Pathology Residency at the University of Calgary in the Department of Pathology at Foothills Hospital and Fellowships in Anatomical Pathology at Royal College of Physicians and Surgeons of Canada and College of American Pathologists FCAP Fellow. He completed a Post-Doctoral Fellowship in Molecular Surgical Pathology at Fox Chase Cancer Center.

In 1998, he joined the faculty at the University of Calgary, where he most recently served as Division Head of Pathology and Laboratory Medicine. He has also served as the Director of the Translational Laboratory at Tom Baker Cancer Centre and the Medical and Scientific Director of the Canadian Breast Cancer Foundation (CBCF)/Alberta Cancer Research Institute (ACRI) Biorepository in Calgary.

Dr. Magliocco has published over 100 peer-reviewed manuscripts and received numerous honors and awards including the Overall Academic Excellence Award at the University of Calgary; the Best Scientific Abstract Award at CARO; and the New Investigator Award from the Alberta Cancer Board. Dr. Magliocco has been continuously funded over the course of the past ten years through peer reviewed grants from the National Cancer Institute of Canada (NCIC) and the Alberta Cancer Board.

Dr. Magliocco’s clinical interest is in the development of novel molecular testing for integration into routine clinical service. His research focuses on understanding the molecular basis of cancer progression including the mechanisms of metastasis and development of resistance to therapeutics including the basis of radiotherapy resistance with a major focus on women’s cancers.

Gary Spitzer, M.D.
Chief Clinical Advisor

Read Bio

Gary Spitzer, M.D.

Chief Clinical Advisor

Dr. Gary Spitzer is a world-renowned oncologist who has vast experience in hematomalignancies and solid tumor malignancies. He was one of the early pioneers in bone marrow transplantation at M.D. Anderson Hospital, and directed hematology/oncology and bone marrow transplantation departments at St. Louis University and Georgetown University. He has also extensively published, with more than 300 manuscripts and articles. Dr. Spitzer has been a leader in the development of curative regimens for Hodgkin’s lymphoma and other hematologic malignancies of which we now consider standard of care, and in vitro studies of drug drug activity in solid tumors. Dr. Spitzer currently takes a very active role in clinical trials involving both solid tumor malignancies and hematopoeitic malignancies. In one of his current roles as clinical director of MolDx, he is well-versed in reviewing and assisting in the development of clinical utility studies for specialized genomic testing in cancer and clinical trials from the industry.

Dr. Spitzer received his M.B. and B.S. from the University of Melbourne. He has served on the boards for several specialties, including: the M.R.A.C.P.: Royal Australian College of Physicians, the American Board of Internal Medicine, the Medical Oncology Recertification, Recertification: Internal Medicine and Oncology, Medical Oncology.

He is currently Epic Emeritus Professor at Epis and Beacon Implementation for Oncology Services. Dr. Spitzer also serves as a consultant MOLDx, and Incyte Pharmaceuticals. He is the recipient of the Leukemia Society of America Scholarship and the Searle Traveling Scholarship.

Dr. Spitzer is the author of over one hundred peer-reviewed manuscripts and serves as a member of the American College of Physicians, the American Society of Clinical Oncology, the American Society of Bone and Marrow Transplantation, the American Society of Hematotherapy and Graft Engineering, and the American Society of Hematology.

Paul Okunieff, M.D.
Founder, DiaCarta

Read Bio

Paul Okunieff, M.D.

Founder, DiaCarta

Dr. Paul Okunieff is board-certified in therapeutic radiology and is among the pioneers of in-vivo nuclear magnetic resonance imaging of tumors. Dr. Okunieff moved to the University of Florida in 2009 from the University of Rochester School of Medicine and Dentistry, where he served as Philip Rubin Professor in radiation oncology and chair of the department of radiation oncology. Prior to his appointment in Rochester in 1998, Dr. Okunieff served as the branch chief of radiation oncology at the National Cancer Institute and as an assistant professor in radiation oncology at Harvard Medical School between 1988 and 1993. Dr. Okunieff earned his medical degree from Harvard Medical School, where he also completed his postdoctoral fellowship in medicine and a fellowship in radiation medicine at Massachusetts General Hospital. He earned bachelor’s degrees in electrical engineering & computer science, and biological science from Massachusetts Institute of Technology. Dr. Okunieff serves as the radiation oncology chair for the Southwest Oncology Group, and a diplomat of the National Board of Medical Examiners where he serves on national committees overseeing the safety and quality of therapeutic radiation delivery.

Sir Walter Bodmer FRCPath, FRS
Professor and Department Head Cancer & Immunogenetics Laboratory

Read Bio

Sir Walter Bodmer FRCPath, FRS

Professor and Department Head
Cancer & Immunogenetics Laboratory
Walter Bodmer FRS CV
Weatherall Institute of Molecular Medicine
John Radcliffe Hospital
Oxford, UK
Scientific Advisor

Sir Walter Bodmer got his BA in mathematics (1956) and then his Ph.D. in population genetics (1959) under Sir Ronald Fisher at Cambridge University. He did his post- doctoral work in molecular biology under Dr Joshua Lederberg at Stanford and then was on the faculty of the Genetics Department in the Stanford University Medical School until 1970, ending up as a Full Professor. He returned to England in 1970 to become Professor of Genetics and head of a new department at Oxford University, and then in 1979 became Director of Research, and later Director General, of the Imperial Cancer Research Fund. Since 1996 he has been head of the cancer and immunogenetics laboratory at the Weatherall Insitute of Molecular Medicine at Oxford University, and from 1996 to 2005 was also the Principal of Hertford College, Oxford.

Walter Bodmer became a Fellow of the Royal Society in 1974, a Foreign Member of the US National Academy of Sciences in 1981 and was Knighted in 1986 for his contributions to science. In 2013 he was awarded a Royal Society Royal Medal for seminal contributions to population genetics, gene mapping and understanding of familial genetic disease. He is the recipient of more than 20 honorary degrees and is an Honorary Fellow or member of more than 15 medical and scientific societies and professional bodies. Walter Bodmer was amongst the earliest to suggest the human genome project and was the second President of HUGO, the Human Genome Organisation.

Sir Walter’s early research was in population genetics, especially the relationship between selection and linkage. He was one of the first to use computers for the simulation of population genetics models starting in 1957. On coming to Stanford he initiated work on the HLA system with Julia Bodmer and Rose Payne, leading to their discovery of what became the HLA -A locus, and also on somatic cell genetics using human-mouse hybrids. His laboratory described some of the first genetic linkages and chromosomal assignments using this technique, and, in collaboration with others, mapped the abl oncogene to chromosome 9, laying the foundations for the discovery of bcr/abl at the 9/22 translocation break point in CML.

Walter Bodmer, with Hugh McDevitt, provided the first explanation for the association of HLA determinants with disease in terms of linkage disequilibrium with functional variation in the HLA region, and then made the suggestion that, quite generally, association studies with genetic markers could be used to search for the genetic basis of multifactorial disease susceptibility. This has been the whole basis for the more recent development of whole genome association studies to discover the basis for genetic susceptibility to common diseases. His laboratory obtained the first monoclonal antibodies to HLA determinants, which have been widely used in immunological research. They were the first to clone the HLA ClassII genes and the first to map the FAP/APC gene to chromosome 5q, following which they have done many studies on mutations in the APC and other genes in colorectal cancer.

More recently, Sir Walter’s laboratory has focused its research on (the fundamental genetics and biology of colorectal cancer and their potential applications, and the characterization and population distribution of genetic diversity in the populations of the British Isles. The latter work has been supported by two successive Wellcome Trust grants and the samples collected are now being used in the WTCC2 studies. The current focus of this work is on establishing the genetic basis of a variety of normal traits, including especially facial features.

Walter Bodmer has also pioneered the hypothesis that rare variants underlie much of the inherited susceptibility to chronic diseases, using colorectal cancer as a model. His laboratory is now working with a panel of more than 100 well characterized colorectal cancer derived cell lines with a major interest in the identification and functional analysis of cancer stem cells using the colorectal cancer derived cell lines as a model, and in using enriched cancer stem cells for preclinical investigation of novel drug responses. Their research also includes studies on antibody dependent killing of colorectal cancer cells in vitro as a prelude to their clinical development for treatment of colorectal cancer and, in collaboration with the Danish Technical University, a microfluidics approach to the analysis of fresh tumor biopsies and rare circulating cancer cells in the blood.

Bernard Levin, MD
Vice-President and Head of the Division of Cancer Prevention

Read Bio

Bernard Levin, MD

Vice-President and Head of the Division of Cancer Prevention and Population Sciences
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Bernard Levin, MD serves as Vice-President and Head of the Division of Cancer Prevention and Population Sciences at The University of Texas M. D. Anderson Cancer Center in Houston. Prof. Levin is a Professor of Medicine at the Department of Gastrointestinal Medicine and Nutrition and the Division of Internal Medicine at the University of Texas and Adjunct Professor in the Department of Medicine at Baylor College of Medicine Houston, Texas. Dr. Levin is a Tenured Professor of Gastroenterology and maintains a clinical practice at the Gastrointestinal Center at M. D. Anderson mostly confined to people with colorectal neoplasia. He serves on the Editorial Board of the Journal of the National Institute and Cancer Epidemiology, Biomarkers & Prevention. Dr. Levin has played a key role in the development of clinical practice guidelines for the screening, prevention and diagnosis of colorectal cancer. Dr. Levin served as the Chair of the National Colorectal Cancer Roundtable from 1998 to 2005. He was also the first recipient of the Betty B. Marcus Chair in Cancer Prevention, which was established to promote professional excellence in cancer prevention. He has published more than 250 articles and edited 10 books, the majority of his work focusing on colorectal cancer. Most recently, he served as the Lead Editor of a book entitled American Cancer Society’s Complete Guide to Colorectal Cancer published in December 2005. He has been the Chairman and a Member of Colorectal Cancer Clinical Advisory Board at GeneNews Limited since July 25, 2007. He serves as a Member of the Scientific Advisory Board of G.i. View Ltd. He completed a research fellowship in biochemistry and a clinical fellowship in gastroenterology at the University of Chicago and was a Member of its faculty until 1984. Prof. Levin holds a M.B.,B.Ch. degree (equivalent to M.D. in the U.S.) from the University of Witwatersrand Medical School, Johannesburg, South Africa.

Scientific Advisors

Frank McCormick, Ph.D.
Founder, Onyx

Read Bio

Frank McCormick, Ph.D.

Founder, Onyx

Dr. McCormick is a molecular biologist and nationally recognized research scientist in cancer biology. He currently serves as director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. He has been the David A. Wood Chair of Tumor Biology and Cancer Research in the department of microbiology and immunology at the University of California, San Francisco and an associate dean of the UCSF School of Medicine since 1997. He is also a member of the UCSF Biomedical Sciences Program and the Herbert Boyer Program in Biological Sciences. Since 1998, Prof. McCormick has served as director of the UCSF Comprehensive Cancer Center.

Prof. McCormick is a distinguished cancer researcher focused on signal transduction pathways in cancer cells, and ways of treating cancer based on these pathways. He is an expert on tumor suppressor genes and the ras pathway.

Prof. McCormick founded Onyx Pharmaceuticals in 1992 and served as the Chief Scientific Officer from 1992 to 1996. He served as Vice President of Therapeutic Research at Chiron Corporation from 1991 to 1992. Prof. McCormick was a Vice President of Discovery Research at Cetus Oncology Corporation from 1981 to 1990, Director of Molecular Biology from 1981 to 1990, and Vice President of Research from 1990 to 1991. He served a variety of senior scientist positions at several biotechnology companies and hospitals, such as Onyx Pharmaceuticals Inc., Exelixis Inc., the Jackson Laboratory, the National Cancer Institute, and Massachusetts General Hospital, Lawrence where he has been the Senior Advisor of Research and Development since 2003.

Dr. McCormick served as the President of the Board of Director’s of American Association for Cancer Research and has served several vital roles on the scientific advisory boards of the following companies: NexGenix Pharmaceuticals Holdings, Inc., Aglaia Biomedical Ventures B.V., OncoCyte Corporation, Pancreatic Cancer Action Network, Inc., Jennerex Biotherapeutics, ORCA Therapeutics B.V., Aduro BioTech, Inc., Dicerna Pharmaceuticals, Inc., Fluidigm Corporation, Iconix Pharmaceuticals, Inc., Iconix Biosciences, Inc., Sagres Discovery, Inc., KineMatik Limited, BiPar Sciences, Inc., and Portola Pharmaceuticals, Inc.

He is a Co-Founder of DNAtriX, Inc. and currently serves as its Director. Prof. McCormick has been a Director of Exelixis Inc. since July 31, 2003 and serves as a member of its Scientific Advisory Board. Prof. McCormick has served as the Director of American Association for Cancer Research since 2008.

In 2002 Prof. McCormick received the prestigious 42nd AACR G.H.A. Clowes Memorial Award for his seminal contribution to studies of the structure and function of oncogenes, which has led to a myriad of novel therapeutic approaches. Prof. McCormick has authored more than 260 scientific publications, edited five books, and holds 21 patents. He has received numerous awards in recognition of his contributions to the field of cancer research. Prof. McCormick serves on the Editorial Board of some of the most prestigious international cancer publications and serves as a board member or advisor to multiple cancer research organizations.

Prof. McCormick was a postdoctoral fellow with Dr. Allen Smith at the Imperial Cancer Research Fund in London, England, and with Professor Seymour S. Cohen at the State University of New York, Stony Brook. Prof. McCormick received his Ph.D. in biochemistry from the University of Cambridge, England in 1975 and his B.S. in biochemistry from the University of Birmingham, England in 1972.

Guo-Liang Yu, Ph.D.
Executive Chairman, Crown Bio
Founder and CEO, Epitomics

Read Bio

Guo-Liang Yu, Ph.D.

Executive Chairman, Crown Bio

Founder and CEO, Epitomics

Dr. Yu is executive chairman of CrownBio and co-founded Epitomics Inc., an antibody based biotechnology company recently acquired by Abcam for $170 M. He served as Chairman, President and CEO of Epitomics Inc. for 10 years.

Dr. Yu’s success is driven by his scientific curiosity and a passion to translate scientific discovery to real products. His challenge is to balance his time between science and business, fun and work, family and community. He came from China to pursue advanced training after graduating from Fudan University in 1984. He obtained his Ph.D. from the University of California, Berkeley where he and Dr. Carol W. Greider discovered telomerase and its mechanism in Dr. Elizabeth Blackburn’s lab. Dr. Blackburn and Dr. Greider received Nobel Prize in 2009 for their discovery. Dr. Yu subsequently joined Dr. Frederick Ausubel’s lab at Harvard to pursue the question how plants defend themselves against pathogens without an immune system. He identified the first plant disease resistance gene. In 1993, when genomics was still in its infancy, Dr. Yu became one of the first Senior Scientists at Human Genome Sciences Inc., identifying human genes for drug discovery. Among the important drug targets he studied, BLys was the first successfully genomic target for the development of a lupus antibody drug, Benlysta, approved by FDA in 2010. In 1998, Dr. Yu began to identify plant genes with economic value for agriculture and bioenergy. He served as Senior Vice President of R&D at Mendel Biotechnology Inc., where his team analyzed the function of a complete set of plant transcription factors. Several valuable traits such as enhanced crop yield, disease resistance, and drought tolerance were identified.

Guo-Liang has co-authored 40 peer-reviewed and is a co-inventor of more than 200 patents. Guo-Liang is the founding president of the Chinese Biopharmaceutical Association and serves on the boards of several professional organizations including Bayhelix, CABS, National Foundation of Cancer Research, Ray Wu Memorial Foundation, the University of the Pacific in the US and China. Dr. Yu is generous in coaching young entrepreneurs and also serves on the board of directors for six start-up companies.

Mickey Urdea, Ph.D.
Board, Bill and Melinda Gates Foundation Diagnostic Forum

Read Bio

Mickey Urdea, Ph.D.

Board, Bill and Melinda Gates Foundation Diagnostic Forum

Mickey is a world-renowned pioneer in personalized medicine. He led the development of world’s first HIV and HCV viral load tests while serving as the head of the Nucleic Acid Diagnostics business unit at Chiron. In 1998, he joined Bayer Diagnostics as Senior Vice President of Nucleic Acid Diagnostics and acting-Chief Scientific Officer of Bayer Diagnostics. Mickey left Bayer in 2000 and co-founded Tethys Bioscience in 2002, and has served as Chairman and Chief Executive Officer. Dr. Urdea received a Ph.D. in biochemistry at Washington State University and held an NIH postdoctoral fellowship at UCSF with William J. Rutter. He has published more than 185 articles and book chapters, and is an inventor of more than 100 issued and pending patents.

Dean Tsao, Ph.D.
Founder and Chairman,
Genemed and PlexBio

Read Bio

Dean Tsao, Ph.D.

Founder and Chairman, Genemed and PlexBio

Dr. Tsao has over 30 years of extended experience in the IVD industry. He received his Ph.D. in biochemistry from the University of Colorado. He is an accomplished scientist and successful entrepreneur with an excellent track record of launching and leading new companies to grow into successful businesses. The companies he has established have developed thousands of products that are currently being used in the diagnosis and research of cancer, HIV, Down syndrome, and numerous other medical conditions. The CISH test, one of the diagnostic products developed under the leadership of Dr. Tsao, targets the protein HER-2, which is an important indicator of breast cancer. Compared to the existing diagnostic method, the CISH test kit is significantly faster, more accurate, and more cost effective. The kit has been approved by the FDA for IVD use.

Investor

BVCF (formally known as BioVeda China Fund) is a growth capital focused private equity fund specializing in China Life Sciences and Healthcare industry. Headquartered in Shanghai, BVCF primarily focuses on equity investments in growth-stage companies in the field of Pharmaceuticals, Biotechnology, Traditional Chinese Medicine, Medical Devices, Healthcare Services, Industrial and Environmental Biotechnology.

Distributors

Bioactiva Diagnostica
Territory: Germany, Egypt, Iran, Turkey, Iraq
Louisenstrasse 137
61348 Bad Homburg
Germany
Tel: +49 (0) 6172 17102-0
E-Mail: bioactiva@bioactiva.de
Genesys Costa Rica
Territory: Costa Rica
Edificio Latitud Dent, Oficina 314
Avenida 5, Barrio Dent, Montes de Oca
Costa Rica
Tel:+506 2253 8090
E-Mail: ventas@genesyscostarica.com
NV Genomics Pvt Ltd
Territory: India (North)
95, Sector – 19, Pocket 3
Dwarka, New Delhi, 110075
India
Tel:+91 9650293975
E-Mail: customersupport@nvgenomics.com
Inbios India
Territory: India (South)
C-48, UGF, Sewak Park
Uttam Nagar, New Delhi, 110059
India
Tel: +91-11-68888485
E-Mail: sales@inbiosindia.com
Sanbio B.V.
Territory: The Benelux
Frontstraat 2c
5405 PB, UDEN
The Netherlands
Tel: +31 (0)413 25 11 15
E-Mail: orders@sanbio.nl
Marvena Diagnostics Ltd.
Territory: Bulgaria
St. Kriprian 44 Str., Mladost 2
Sofia, 1799
Bulgaria
Tel: + 359 2 974 89 44
E-Mail: office@marvena-dx.com
AIT Biotech
Territory: Singapore, Thailand, Malaysia, Indonesia, Cambodia, Philippines
#05-15 Tic Tech Centre
25 Pandan Crescent, 128477
Singapore
Tel: +65 6778 6822
E-Mail: enquiries@aitbiotech.com
Onwon Trading LTD
Territory: Hong Kong
Room 1907, Remington Centre
23 Hung To Road
Kwun Tong
Hong Kong
Tel: (852) 2757 7569
E-Mail: info@onwon.com.hk

Join the DiaCarta Team

We are seeking highly talented and creative people to join us in advancing genetic testing and molecular diagnostics. If you share our dedication to the science of impact, please contact us.

The following information will allow us to better serve your specific needs. Please complete the following fields. Sales related request could also email order@diacarta.com.
  • *Required fields

DiaCarta, Inc.

2600 Hilltop Drive

Building B, 3rd Floor

Richmond, CA 94806

1.800.246.8878

Get Directions

Hilltop Dr, Richmond, CA 94806, USA